Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer., J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882

Bancroft, 2014, Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study., Eur Urol, 66, 489, 10.1016/j.eururo.2014.01.003

Pomerantz, 2017, The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer., Cancer, 123, 3532, 10.1002/cncr.v123.18

Giri, 2018, Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017., J Clin Oncol, 36, 414, 10.1200/JCO.2017.74.1173

Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer., N Engl J Med, 375, 443, 10.1056/NEJMoa1603144

Robinson, 2015, Integrative clinical genomics of advanced prostate cancer., Cell, 161, 1215, 10.1016/j.cell.2015.05.001

Leongamornlert, 2014, Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease., Br J Cancer, 110, 1663, 10.1038/bjc.2014.30

Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death., Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033

Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer., Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022

Lincoln, 2015, A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients., J Mol Diagn, 17, 533, 10.1016/j.jmoldx.2015.04.009

Nykamp, 2017, Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria., Genet Med, 19, 1105, 10.1038/gim.2017.37

Hampel, 2015, A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment., Genet Med, 17, 70, 10.1038/gim.2014.147

Shindo, 2017, Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma., J Clin Oncol, 35, 3382, 10.1200/JCO.2017.72.3502

Lecarpentier, 2017, Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores., J Clin Oncol, 35, 2240, 10.1200/JCO.2016.69.4935

Stoll, 2018, The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine., Am J Med Genet C Semin Med Genet, 178, 24, 10.1002/ajmg.c.v178.1

Cohen, 2016, A collaborative approach to cancer risk assessment services using genetic counselor extenders in a multi-system community hospital., Breast Cancer Res Treat, 159, 527, 10.1007/s10549-016-3964-z

Buchanan, 2016, Alternate service delivery models in cancer genetic counseling: a mini-review., Front Oncol, 6, 120, 10.3389/fonc.2016.00120

National Comprehensive Cancer Network. Prostate cancer (version 3.2018). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Accessed July 27, 2018.

National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian (version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Accessed July 30, 2018.

National Comprehensive Cancer Network. Genetic/familial high-risk assessment: colorectal (version 1.2018). https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf Accessed July 27, 2018.